



Recent Advancements in Malignant Pleural Mesothelioma: Diagnosis, Treatment, and Molecular Mechanisms

Guest Editor:

Dr. Sara Ricciardi

Unit of Thoracic Surgery, Azienda
Ospedaliera San Camillo
Forlanini, Carlo Forlanini
Hospital, Circonvallazione
Gianicolense 87, 00152 Rome,
Italy

Deadline for manuscript
submissions:

closed (31 March 2025)

Message from the Guest Editor

Dear Colleagues,

Malignant pleural mesothelioma (MPM) is a dismal and rare disease caused by asbestos exposure. Since asbestos use peaked around 1980 and the latency time to develop MPM is around 20 to 50 years, the number of deaths from MPM in Europe is expected to peak in 2020–2025.

The optimal treatment for mesothelioma remains under debate; moreover, there is no international agreement on the role of surgery with curative intent.

FUTURE: We need to address some open questions:

- What is the role of neoadjuvant treatment?
- Does the immunotherapy revolutionize the approach to MPM as with what happened to NSCLC?
- Which is the best timing for surgery in multimodal treatment?
- Can Artificial Intelligence predict the outcomes of MPM patients?

The aim of this Special Issue is debating and answering the most important controversies about this cruel disease.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Shahid Ahmed

1. College of Medicine, University of Saskatchewan, Saskatoon, SK S7N5E5, Canada
2. Saskatchewan Cancer Agency, Saskatoon Cancer Center, Saskatoon, SK S7N5H5, Canada

Message from the Editor-in-Chief

I am honored and enthusiastic to serve as Editor-in-Chief of *Current Oncology*. Since its establishment in 1994, *Current Oncology* has been playing an important role in the advancement of cancer care by disseminating new knowledge in the cancer care continuum. *Current Oncology* is affiliated with several key cancer societies and provides a global platform to share scientific progress in oncology. We strive for high standards and work together to maintain a rigorous and unbiased peer review process to publish high-quality articles. We have an outstanding editorial team which is committed to the success of *Current Oncology*.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase,** and **other databases.**

Journal Rank: JCR - Q2 (Oncology)

Contact Us

Current Oncology Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/currenncol
currentoncology@mdpi.com
[X@CurrentOncology](https://twitter.com/CurrentOncology)